Dallas, TX (PRWEB) June 08, 2012
The Pradaxa Resource Center, a patient advocacy group, is alerting patients who have taken or may be prescribed the drug Pradaxa of a new report indicating the FDA received more complaints of patient death among Pradaxa users last year than with any other drug.
Anyone who has suffered a bleeding episode after taking Pradaxa or lost a loved one is urged to speak with a lawyer about their legal rights as soon as possible.
Pradaxa is a popular anticoagulant prescribed to patients suffering from atrial fibrillation in order to prevent strokes. According to The Wall Street Journal on April 24, 2012, the drug reached blockbuster status after reaching the $1 billion sales mark for the 12-month period ending in February.
Unfortunately, the FDA warned on December 7, 2011 that it was investigating the safety of Pradaxa after receiving higher than expected reports of injury or death. Last month on May 25th, the European Medicines Agency also issued a statement saying that warnings should be added to give doctors and patients a clearer picture of the risks.
Now, the Philadelphia Inquirer is reporting that Pradaxa led all other medications in 2011 for number of deaths reported to the FDA. In an article published June 6, 2012, the paper cites a report from the Institute for Safe Medication Practices’ QuarterWatch program, which tracks reports to the FDA’s MedWatch.
The Inquirer noted that Pradaxa exceeded all other medications in the categories of total adverse reports (3,781), deaths (542), hemorrhage (2,367), acute renal failure (291), and stroke (644). In contrast, there were only 731 reports of hemorrhage and 72 deaths associated with Coumadin.
Although all anticoagulants carry a risk of internal bleeding, most have a reversal agent available to doctors in emergency. A March 6, 2012 report by the Journal of Neurosurgery detailed a specific case and complaints by doctors that once Pradaxa causes internal bleeding in a patient, there is very little they can do to stop it.
Due to the number of lawsuits expected over Pradaxa side effects, a motion was recently filed to consolidate the cases into one central federal court. The Motion was filed on May 30, 2012 in Case MDL No. 2385 IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois. In the Motion, lawyers state they expect as many as 500 cases will be filed.
Anyone affected by Pradaxa side effects is urged to speak with a lawyer about their legal options. However, due to the specialized nature of these federal MDL cases, only certain lawyers can help. The Pradaxa Resource center works only with lawyers who are already filing these cases.
For the original version on PRWeb visit: http://www.prweb.com/releases/prwebpradaxa/death/prweb9585525.htm